Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report

A 28-year-old woman with autosomal dominant familial hypercholesterolemia (FH) with a probable coexistent polygenic contribution causing very high low-density lipoprotein-cholesterol (LDL-C) levels, started therapy with the proprotein convertase subtilisin/kexin type 9-inhibitor (PCSK9i) alirocumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Allevi, Massimiliano, Sarnari, Silvia, Giulietti, Federico, Spannella, Francesco, Di Pentima, Chiara, Sarzani, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326624/
https://www.ncbi.nlm.nih.gov/pubmed/37424909
http://dx.doi.org/10.3389/fcvm.2023.1181720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326624/
https://www.ncbi.nlm.nih.gov/pubmed/37424909
http://dx.doi.org/10.3389/fcvm.2023.1181720

Ejemplares similares